These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 33334865)

  • 1. Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: a systematic review and meta-analysis.
    Bae S; Kim SR; Kim MN; Shim WJ; Park SM
    Heart; 2021 Mar; 107(5):373-380. PubMed ID: 33334865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-existing cardiovascular disease rather than cardiovascular risk factors drives mortality in COVID-19.
    O'Gallagher K; Shek A; Bean DM; Bendayan R; Papachristidis A; Teo JTH; Dobson RJB; Shah AM; Zakeri R
    BMC Cardiovasc Disord; 2021 Jul; 21(1):327. PubMed ID: 34217220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Cardiovascular Risk Factors and Cardiovascular Diseases on Outcomes in Patients Hospitalized with COVID-19 in Daegu Metropolitan City.
    Park BE; Lee JH; Park HK; Kim HN; Jang SY; Bae MH; Yang DH; Park HS; Cho Y; Lee BY; Nam CW; Lee JB; Kim U; Chae SC;
    J Korean Med Sci; 2021 Jan; 36(2):e15. PubMed ID: 33429474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of a gluten-reduced or gluten-free diet for the primary prevention of cardiovascular disease.
    Schmucker C; Eisele-Metzger A; Meerpohl JJ; Lehane C; Kuellenberg de Gaudry D; Lohner S; Schwingshackl L
    Cochrane Database Syst Rev; 2022 Feb; 2(2):CD013556. PubMed ID: 35199850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of pre-existing comorbidities with mortality and disease severity among 167,500 individuals with COVID-19 in Canada: A population-based cohort study.
    Ge E; Li Y; Wu S; Candido E; Wei X
    PLoS One; 2021; 16(10):e0258154. PubMed ID: 34610047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical risk factors for mortality of hospitalized patients with COVID-19: systematic review and meta-analysis.
    Xiang G; Xie L; Chen Z; Hao S; Fu C; Wu Q; Liu X; Li S
    Ann Palliat Med; 2021 Mar; 10(3):2723-2735. PubMed ID: 33549005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Age at Onset of Menopause and Time Since Onset of Menopause With Cardiovascular Outcomes, Intermediate Vascular Traits, and All-Cause Mortality: A Systematic Review and Meta-analysis.
    Muka T; Oliver-Williams C; Kunutsor S; Laven JS; Fauser BC; Chowdhury R; Kavousi M; Franco OH
    JAMA Cardiol; 2016 Oct; 1(7):767-776. PubMed ID: 27627190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of cardiovascular disease and acute cardiac injury on fatal COVID-19: a meta-analysis.
    Long J; Luo Y; Wei Y; Xie C; Yuan J
    Am J Emerg Med; 2021 Oct; 48():128-139. PubMed ID: 33895644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients.
    Dessie ZG; Zewotir T
    BMC Infect Dis; 2021 Aug; 21(1):855. PubMed ID: 34418980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19).
    Guo T; Fan Y; Chen M; Wu X; Zhang L; He T; Wang H; Wan J; Wang X; Lu Z
    JAMA Cardiol; 2020 Jul; 5(7):811-818. PubMed ID: 32219356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 and its cardiovascular effects: a systematic review of prevalence studies.
    Pellicori P; Doolub G; Wong CM; Lee KS; Mangion K; Ahmad M; Berry C; Squire I; Lambiase PD; Lyon A; McConnachie A; Taylor RS; Cleland JG
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013879. PubMed ID: 33704775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Smoking cessation for secondary prevention of cardiovascular disease.
    Wu AD; Lindson N; Hartmann-Boyce J; Wahedi A; Hajizadeh A; Theodoulou A; Thomas ET; Lee C; Aveyard P
    Cochrane Database Syst Rev; 2022 Aug; 8(8):CD014936. PubMed ID: 35938889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta-analysis of randomized control trials.
    Seidu S; Achana FA; Gray LJ; Davies MJ; Khunti K
    Diabet Med; 2016 Mar; 33(3):280-9. PubMed ID: 26282461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of Cardiovascular Diseases Associated With Medications Used in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-analysis.
    Zhang L; Yao H; Li L; Du Rietz E; Andell P; Garcia-Argibay M; D'Onofrio BM; Cortese S; Larsson H; Chang Z
    JAMA Netw Open; 2022 Nov; 5(11):e2243597. PubMed ID: 36416824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of metabolic and cardiovascular disease on COVID-19 mortality: A systematic review and meta-analysis.
    Sahni S; Gupta G; Sarda R; Pandey S; Pandey RM; Sinha S
    Diabetes Metab Syndr; 2021; 15(6):102308. PubMed ID: 34673359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of treatments tested in COVID-19 patients with cardiovascular disease. A meta-analysis.
    Ben-Aicha S; Buchanan J; Punjabi P; Emanueli C; Moscarelli M
    Perfusion; 2023 Mar; 38(2):373-383. PubMed ID: 35220805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic versus opportunistic risk assessment for the primary prevention of cardiovascular disease.
    Dyakova M; Shantikumar S; Colquitt JL; Drew CM; Sime M; MacIver J; Wright N; Clarke A; Rees K
    Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD010411. PubMed ID: 26824223
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.